FCSC Fibrocell Science Inc

2.42
-0.15  -6%
Previous Close 2.57
Open 2.58
Price To book 4.80
Market Cap 35.56M
Shares 14,693,000
Volume 30,478
Short Ratio 1.78
Av. Daily Volume 105,921

SEC filingsSee all SEC filings

  1. 8-K - Current report 17859699
  2. 8-K - Current report 17834453
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828553
  4. 8-K - Current report 17828537
  5. 8-K - Current report 17824773

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued December 18, 2009. Approved June 22, 2011.
Laviv
Wrinkles
Phase 2 endpoints not met - June 2016
azficel-T
Chronic Dysphonia
Phase 1/2 initiation of dosing announced February 23, 2017. Phase 1 data due 3Q 2017.
FCX-007
Recessive dystrophic epidermolysis bullosa

Latest News

  1. Fibrocell to Present at Inaugural Cell & Gene Exchange 2017
  2. Fibrocell Science reports 1Q loss
  3. Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights
  4. Investor Network: Fibrocell Science, Inc. to Host Earnings Call
  5. Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
  6. Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
  7. Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
  8. Fibrocell to Present at 7th Annual World Orphan Drug Congress USA 2017 and 5th Annual Cell & Gene Therapy Investor Day
  9. ETFs with exposure to Fibrocell Science, Inc. : April 7, 2017
  10. Fibrocell Regains Compliance with NASDAQ Listing Requirements
  11. Fibrocell Science, Inc. :FCSC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  12. Fibrocell Science, Inc. :FCSC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  13. Fibrocell Announces One-for-Three Reverse Stock Split
  14. Fibrocell Reports 2016 Financial Results and Recent Operational Highlights
  15. Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial Results and Recent Operational Highlights
  16. Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million
  17. Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results

SEC Filings

  1. 8-K - Current report 17859699
  2. 8-K - Current report 17834453
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828553
  4. 8-K - Current report 17828537
  5. 8-K - Current report 17824773
  6. DEF 14A - Other definitive proxy statements 17789928
  7. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17681995
  8. 8-K - Current report 17680334
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17678842
  10. 8-K - Current report 17676828